Chief investigator - Professor Paresh Vyas, University of Oxford
A first-in-human, first-in-class phase I dose escalation trial of humanized Anti-CD47 monoclonal antibody Hu5F9-G4 in acute myeloid leukaemia (AML)
Amount awarded: £308,471
Award start date: 27 Mar 2015
Recruitment start date: 27 Nov 2015
Award duration: 3 years (39 months)

Researchers have found that AML cells have a large amount of a protein called CD47. This protein can protect the cancer cells by preventing the body’s immune system removing and destroying them.

Hu5F9-G4 is a type of biological therapy called a monoclonal antibody. It works by blocking the signals of CD47 that protect the AML cells. Early studies have shown that Hu5F9-G4 can successfully eliminate AML cells in laboratory experiments, so researchers now want to see if Hu5F9-G4 can help treat people with AML.

The aims of this trial are to:

  • Find out how well Hu5F9-G4 works for people with AML
  • See how safe it is
  • Find the best dose of Hu5F9-G4
  • See what the side effects are
  • How Hu5F9-G4 works in the body

You may be eligible to join this trial if:

  • You have AML that has come back after treatment, or has continued to get worse during treatment
  • You are 18 years of age or older